Pharmaceutical Executive October 2, 2024
Immorta Bio’s president discusses the company’s work with age-related diseases.
It’s no secret that as people get older, they face more health risks at a higher rate. Dr. Thomas Ichim, president and chief scientific officer at Immorta Bio, spoke with Pharmaceutical Executive about his company’s work focused on age related diseases and the unique challenges this brings.
Pharmaceutical Executive: What made Immorta decide to focus on aging related diseases?
Dr. Thomas Ichim: We recognized that aging is the primary risk factor for numerous diseases, characterized by the gradual decline of organs and tissues, and an increased likelihood of disease onset and progression, including cancer, cardiovascular disease, metabolic disorders, and neurodegeneration. The field of aging science and longevity technologies has advanced significantly,...
Today's Sponsors
Today's Sponsor